SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Charming Medical, Limited (NASDAQ: MCTA) securities between October 10, 2025 and November 12, 2025. The Company claims to “enhance[] the quality of life from the inside out by integrating Traditional Chinese Medicine (TCM) wellness practices with modern technology.” For more information, submit a form, email attorney Aaron Dumas, Jr., or g ...

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) for alleged fraudulent activities related to stock promotions and misinformation that led to significant stock price inflation during the class period from October 10, 2025, to November 12, 2025 [8]. Allegation Details - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [8]. - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [8]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that inflated the stock price [8]. Stock Price Movement - Charming's share price increased from the initial public offering price of $4.00 to an all-time high of $29.36 per share, despite no fundamental news justifying such a spike [8]. - Investigations revealed that the stock was subject to an illicit promotion scheme that artificially inflated its price through sensational claims made by impersonators in online forums and social media [8]. Regulatory Actions - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended as the company has not provided the required information to lift the suspension [8].

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ:MCTA) for alleged fraudulent activities related to stock promotions and misinformation that led to significant stock price inflation during the class period from October 10, 2025, to November 12, 2025 [6]. Group 1: Allegations and Legal Actions - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [6]. - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [6]. - The stock price surged from an initial public offering price of $4.00 to an all-time high of $29.36 per share without any fundamental news justifying such a spike [6]. Group 2: Trading Suspension and Investor Rights - Trading of Charming's stock was halted by the SEC on November 12, 2025, due to the company's failure to provide required information to lift the suspension [6]. - Investors who purchased Charming shares during the class period and suffered losses are encouraged to contact Bragar Eagel & Squire, P.C. to discuss their legal rights and options [4][6]. Group 3: Firm Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in securities litigation and has a nationwide practice [5].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Charming (MCTA) To Contact Him Directly To Discuss Their Options If you purchased or acquired Charming Medical common stock between October 10, 2025, and November 12, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Forunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- What’ ...

NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Charming Medical Ltd. (NASDAQ: MCTA) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Charming securities between October 10, 2025 and November 12, 2026, b ...

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Ltd. for alleged securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves allegations that Charming and certain officers and/or directors engaged in securities fraud [2]. - Investors have until February 17, 2026, to request to be appointed as Lead Plaintiff if they purchased Charming securities during the Class Period [2]. Group 2: Stock Performance and SEC Action - On November 11, 2025, Charming's stock closed at $29.36, with an intraday high of $31.70, and had approximately 17.18 million shares outstanding, resulting in a market capitalization of around $504 million [4]. - Following this, the SEC halted trading of Charming securities from November 12 through 25, 2025, due to allegations of price manipulation through social media, which was part of a "pump-and-dump" scheme [4].

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) for alleged fraudulent activities related to stock promotion schemes that misled investors during the period from October 10, 2025, to November 12, 2025 [6]. Allegation Details - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [6]. - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [6]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that inflated the stock price [6]. Stock Performance - Charming's share price increased from an initial public offering price of $4.00 to a peak of $29.36 per share, despite no fundamental news justifying such a rise [6]. - The stock was subject to an illicit promotion scheme that created a buying frenzy among retail investors through sensational claims made by impersonators in online forums and social media [6]. Regulatory Actions - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended as the company has not provided the necessary information to lift the suspension [6]. Legal Options for Investors - Investors who purchased Charming shares and suffered losses are encouraged to contact Bragar Eagel & Squire, P.C. for legal options, with a deadline of February 17, 2026, to apply as lead plaintiff in the lawsuit [4][6].

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Charming Medical Limited (“Charming Medical” or the “Company”) (NASDAQ: MCTA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Charming Medical and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the clas ...

Core Viewpoint - A class action has been filed against Charming Medical, Limited (NASDAQ: MCTA) for allegedly engaging in a fraudulent stock promotion scheme that misled investors and artificially inflated its stock price [1][2]. Allegations - The complaint alleges that Charming Medical failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [2]. - Insiders and affiliates reportedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that were driving the stock price [2]. Stock Price Surge - In the weeks leading up to November 12, 2025, Charming's share price increased from the initial public offering price of $4.00 to an all-time high of $29.36 per share, despite a lack of fundamental news justifying such a rise [3]. - Investigations revealed that the stock was subject to an illicit social-media-based promotion scheme that created a buying frenzy among retail investors through sensational but baseless claims [3]. - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended due to the company's failure to provide required information to regulators [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit papers to the court by February 17, 2026, but participation is not required to be eligible for recovery [4]. - Individuals can choose to remain absent class members if they do not wish to take action [4]. Legal Representation - All representation in the class action is on a contingency fee basis, meaning shareholders pay no fees or expenses [5].

Core Viewpoint - Charming Medical Limited is facing a lawsuit for alleged violations of securities laws, which may impact its financial standing and investor confidence [1] Group 1 - The lawsuit has been initiated by the DJS Law Group, indicating potential legal challenges for Charming Medical Limited [1] - The allegations pertain to securities law violations, which could lead to significant financial repercussions for the company [1]